MedTrace Logo

Biomarkers to Distinguish Benign From Malignant Thyroid Neoplasm

NCT01433809 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1

Last updated 2014-01-22

No results posted yet for this study

Summary

This protocol will evaluate microRNA biomarkers in blood and fine-needle aspirate biopsies (FNAB) of thyroid nodules. MicroRNA profiles will be determined and evaluated for their utility in pre-operative diagnosis, in particular to distinguish benign from malignant throid neoplasms. Post-surgical fresh-frozen thyroid cancer tissue will be assessed for somatic mutations, mRNA, and microRNA expression patterns. FFPE tissue will be used to obtain H\&E and unstained slides to specific biomarker results using immunohistochemistry.

Conditions

  • Cancer of the Thyroid
  • Neoplasms, Thyroid
  • Thyroid Adenoma
  • Thyroid Cancer
  • Thyroid Carcinoma

Sponsors & Collaborators

  • Norman Eberhardt

    lead OTHER

Principal Investigators

  • Norman Eberhardt, PhD · Mayo Clinic

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2013-05-31
Completion
2013-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01433809 on ClinicalTrials.gov